Literature DB >> 1458664

Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly.

J Lauharanta1.   

Abstract

Altogether 157 patients with onychomycosis affecting not more than 80% of the surface area of nail with intact lunula and matrix were treated once weekly for up to 6 months with amorolfine nail lacquer (2 or 5%) in a double-blind randomized design. Clinical examinations were carried out before, monthly during, and 1 and 3 months after therapy. Mycological examinations were performed before, 1 and 3 months after therapy. One hundred patients were evaluated. According to the overall assessment by the investigators, which was based on the clinical response and mycological findings, there was cure in 12%, improvement in 55% and failure in 33+ of the 2% group. The corresponding figures in the 5% group were: cure in 38%, improvement in 32% and failure in 30%. The difference in the number of cures was statistically significant in favour of the 5% nail lacquer. The most common pathogens isolated were Trichophyton rubrum in 59% of cases and Trichophyton mentagrophytes in 22%. Three months after the end of the treatment the mycological culture was negative in 55% of the 2% group and in 60% of the 5% group. Both concentrations were well tolerated. Only three patients (2%) experienced mild local adverse events. No systemic side-effects occurred and no patient discontinued treatment due to an adverse event. In conclusion, the 5% nail lacquer was more effective than the 2% nail lacquer when used once weekly for up to 6 months for the treatment of mild to moderate onychomycosis, and both concentrations were well tolerated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458664     DOI: 10.1111/j.1365-2230.1992.tb00277.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  17 in total

1.  Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.

Authors:  Tsuyoshi Shimamura; Nobuo Kubota; Saori Nagasaka; Taku Suzuki; Hideki Mukai; Kazutoshi Shibuya
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

2.  In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes.

Authors:  M Ghannoum; N Isham; L Long
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

Review 3.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Pharmacoeconomic analysis of topical treatments for tinea infections.

Authors:  N H Shear; T R Einarson; S R Arikian; J J Doyle
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

5.  Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis.

Authors:  Bianca Maria Piraccini; Michela Starace; Anders Toft
Journal:  Dermatology       Date:  2017-08-05       Impact factor: 5.366

Review 6.  Onychomycosis in the elderly : drug treatment options.

Authors:  Daniel S Loo
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Management of onychomycoses.

Authors:  M Niewerth; H C Korting
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 8.  Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

Authors:  M Haria; H M Bryson
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 9.  Skin conditions of baseball, cricket, and softball players.

Authors:  Joshua A Farhadian; Brook E Tlougan; Brian B Adams; Jonathan S Leventhal; Miguel R Sanchez
Journal:  Sports Med       Date:  2013-07       Impact factor: 11.136

Review 10.  The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.